Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
14 août 2023 08h05 HE
|
Outlook Therapeutics, Inc.
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration...
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
01 août 2023 08h45 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
15 mai 2023 08h05 HE
|
Outlook Therapeutics, Inc.
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular...
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
27 avr. 2023 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
13 mars 2023 07h00 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
14 févr. 2023 08h05 HE
|
Outlook Therapeutics, Inc.
Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010 /...
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
07 févr. 2023 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
19 janv. 2023 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
09 janv. 2023 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
29 déc. 2022 09h05 HE
|
Outlook Therapeutics, Inc.
Attained U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic...